• search

Aurigene is a contract research, development and manufacturing organization offering truly integrated CRO (discovery) and CDMO services for the small and large molecules to global innovative pharma and biotech companies. 
Beyond science, our operations are rooted in the fundamental principles of compliance, information security, quality, and sustainability. As an environmentally responsible company, we continue delivering on our ESG goals. We became water-positive in 2023 and are working on ambitious goals to reduce our carbon footprint. In numbers, we aim to switch to 100% renewable power by 2030 and achieve carbon neutrality in our direct operations (Scope 1 and Scope 2 emissions) by 2030 and a 12.5% reduction in indirect carbon emissions across our supply chain (Scope 3 emissions) by 2030.

 

Our Integrated Services for Small and Large Molecules

In the discovery space, Aurigene boasts a legacy of more than 25 years of operations and has long-term partnerships with two of the top five pharmaceutical companies. We offer small molecule discovery services, including chemistry, biology, and integrated services across the life cycle of drug discovery, from target identification to IND filing. We operate in a flexible manner, offering our services in FTE and/or FFS mode; integrated and/or standalone mode.

Leading CRO/CDMO and a long-term partner

We are uniquely positioned to serve our customers and accelerate their journey to the clinic from discovery to commercialization by nurturing long-term partnerships.

Read more about our infrastructure to see how we are positioned to provide end-to-end services:

Read More

 

Why Aurigene Pharmaceutical Services?

20+

years’ experience

900+

scientists

125+

global clients

600+

projects

19

NCEs 
commercialized

16

USFDA inspected 
cGMP facilities

6

Biologics 
commercialized

3

manufacturing countries 
UK, Mexico, India

 

Virtual Tour

 
quots

Client Speak

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

section

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

rightCaptcha

ADMET Predictive Models in Aurigene

ADMET Predictive Models in Aurigene.AI

What makes a drug effective and safe for human use?The answer lies in understanding ADMET, which stands for absorption, distribution, metabolism, excretion, and toxicity. These parameters are critical components of pharmacokinetics, describing how a drug is processed in the body. ADMET properties determine the pharmacokinetic profile of a drug, influencing its ef...

Read More
CDMO white paper

Advancement in personalized medicine and how the CRDMO industry is part of the solution

Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role in enabli...

Read More
Overcoming challenges with cyclic peptides for In-vitro experiments and Bioanalysis

Overcoming challenges with cyclic peptides for In-vitro experiments and Bioanalysis

Project Requirement:Cyclic peptides were to be analyzed for Kinetic solubility, Chrom Log D, MDCK, PAMPA, & Caco2 experiments, while overcoming the challenges associated with the impact of cyclization of peptides on in vitro experiments and bioanalysisWhat were the challenges!1. Nonspecific Binding (NSB)2. Precipitation of peptides while spiking DMSO stock to...

Read More

Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques

2025

Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack